Genenta Science to Rebrand as Saentra Forge, Seeks Acquisitions in Defense and Biotech
Genenta Science, pending shareholder approval to rebrand as Saentra Forge, is expanding beyond biotech into defense, aerospace and cybersecurity by targeting selective acquisitions of high-quality companies. It has engaged DC Advisory to explore collaboration on its Temferon platform but reports no active partner discussions to date.
1. Strategic Pivot to Saentra Forge
Genenta Science announced its intention to adopt the corporate name Saentra Forge, subject to shareholder approval, evolving into a sovereign-aligned industrial consolidator focused on specialized technologies in biotech, defense, aerospace and cybersecurity.
2. Targeted Acquisition Focus
The company plans to pursue selective acquisitions of privately held scale-ups in Italian national-security-regulated sectors, offering capital, industrial capabilities and indirect access to U.S. public markets via its Nasdaq listing.
3. Temferon Platform Development
Genenta has retained DC Advisory to identify potential collaborators for its original Temferon immunotherapy platform but confirms no active discussions or partners have been secured to date.
4. Insider Shareholder Confidence
Founder-scientists Luigi Naldini and Bernhard Gentner, along with CEO Pierluigi Paracchi, have increased their holdings and oppose any sale of shares until Temferon achieves meaningful third-party validation.